Friday, December 13, 2019

Surgery for Recurrent Ovarian Cancer Does Not Improve Survival

I must say that I had to read this article twice because the study results were just so stunning to me! Again, I have Betsy to thank for sending this to me.

Essentially, women who have surgery for recurrent OC (epithelial, primary peritoneal or fallopian tube cancers) were included.

The results showed that women who did not have surgery lived 14 months longer than those who had surgery plus chemo and Avastin. They also had a better quality of life given that they didn't have all the post-op hassles to deal with.

To read about this in (far) more interesting detail, I'm providing several links: one from the National Cancer Institute (NCI) which summarizes the study and another from National Center for Biotechnology Information (NCBI) that provides the abstract of the study itself published by NCI.

Here they are:
Surgery for Recurrent Ovarian Cancer Does Not Improve Survival 

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

No comments:

Post a Comment